New treatment approach kills lymphoma while sparing healthy cells in mice
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
List view / Grid view
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
Researchers engineered the Disque Platform, a high-fidelity culture system, to enable them to screen drugs able to promote β cell proliferation.
Researchers have found that spermidine can ramp up autophagy and boost T-cell function, potentially increasing the protective effects of vaccines in older adults.
Associate Professor Pandurangan Vijayanand from La Jolla Institute for Immunology discusses his study into the body’s immune response to SARS-CoV-2 and why this can vary.
UK Health Secretary Matt Hancock has said there is a mutated form of SARS-CoV-2 that may be causing a rise in infections in South East England.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
New research has demonstrated in mouse models that the SHP-1 protein limits the capacity of dendritic cells, making it a target for a leishmaniasis vaccine.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Scientists report their phage-based inhaled vaccine delivery system elicited a robust antibody response in both mice and non-human primates.
In a new report, Elsevier describes how it used text mining to reveal the top trends in pancreatic cancer research – this article outlines the findings.
Elevated levels of a biomarker related to blood vessel damage have been found in all children with SARS-CoV-2 infection.
A long-term study of macaques given mitochondrial replacement therapy (MRT) found that both treated individuals and their offspring were healthy and developed normally.
Researchers have shown how increased YTHDF3 expression correlates with brain cancer metastases, making it a target for the condition.
Engineered deubiquitinases combines a synthetic nanobody that recognises a protein that can rescue proteins tagged for destruction.